Global Bioinformatics Services Market Size, 2031

Bioinformatics services apply computational methods, software and statistical expertise to biological data so that researchers and clinicians can turn raw measurements into usable findings. Providers handle sequence alignment, variant calling, genome assembly, transcriptomics, proteomics, metabolomics, structural modelling, pathway analysis and the storage, security and sharing of very large datasets. Work is delivered as outsourced projects, long-term analysis partnerships, managed cloud pipelines, custom software development and consulting on study design and regulatory submissions. Demand comes from drug discovery teams, clinical laboratories, hospitals, agricultural breeders, public health agencies and academic consortia, all of which generate more data than their in-house teams can analyse. Participants include Illumina, Thermo Fisher Scientific, Qiagen, Agilent, PerkinElmer, Eurofins, Novogene, BGI Genomics, DNAnexus, Seven Bridges, Genedata, Schrödinger, Dassault Systèmes and a large group of specialist contract analysis firms and academic core facilities. Services sit between laboratory instruments and scientific decisions, so their value depends on accuracy, reproducibility and speed. Customers range from large pharmaceutical groups that outsource peaks in workload to small biotechnology firms and hospital laboratories with no analytical staff, which keeps the provider base varied. Contracts typically run from a few weeks for a single study to several years for managed pipelines.

The market is shaped by the steady fall in sequencing cost since the first human genome was completed in 2003, which has moved bottlenecks from data generation to interpretation. Population genomics programmes, single-cell and spatial methods, long-read sequencing and multi-omics studies create data volumes that need cloud computing and specialised pipelines. Artificial intelligence has added protein structure prediction, as shown by AlphaFold, whose creators received the 2024 Nobel Prize in Chemistry, and machine learning for target discovery and variant interpretation. Rules on data protection, cross-border transfer and software validation now influence how services are delivered. The European Health Data Space regulation entered into force in March 2025, and the United States National Institutes of Health tightened security expectations for controlled-access data in 2025. Through 2031, buyers will look for secure cloud analysis, transparent methods, skilled staff and interoperable data standards, while price competition and talent shortages remain constraints. Between 2020 and 2026 the shift toward cloud delivery accelerated, and by 2031 most routine analysis is expected to run on managed platforms, leaving specialist interpretation as the main area of differentiation.

Drivers •Rising Data Volumes from Genomics and Multi-Omics: Sequencing, single-cell, spatial and proteomic instruments generate terabytes per study, and national programmes such as the United Kingdom Biobank and the All of Us Research Program add population-scale data. Few laboratories have the staff or computing needed to process these files, so they outsource alignment, annotation, quality control and statistical analysis. Multi-omics studies that combine several data types need specialist integration methods, and clinical sequencing for cancer and rare disease creates recurring demand for validated variant interpretation pipelines.

•Growth of Drug Discovery, Precision Medicine and Artificial Intelligence: Pharmaceutical and biotechnology companies use computational biology to find targets, select patients, interpret biomarkers and design molecules, and they often buy expertise instead of building whole teams. Precision oncology, pharmacogenomics and companion diagnostics depend on reliable interpretation of genetic variants. Advances in machine learning, including protein structure and language models, widen what can be analysed and increase demand for providers that can train, validate and operate these models with regulated data.

Challenges •Data Privacy, Security and Regulatory Complexity: Genomic and health data are sensitive, and rules such as the European General Data Protection Regulation, the United States Health Insurance Portability and Accountability Act and national localisation laws limit where data can be stored and analysed. Providers must invest in encryption, access control, audit trails and certifications, and cross-border projects need legal review. In 2025 the United States restricted some access to controlled-access data from certain countries, showing how policy can change service delivery quickly.



•Talent Shortages, Standardisation and Pricing Pressure: Qualified bioinformaticians, data engineers and statisticians are in short supply, and salaries are high, which limits capacity and raises delivery costs. Pipelines, file formats and reference genomes vary between laboratories, making results hard to reproduce or compare. Open-source tools and cloud platforms with usage-based pricing also push down prices for routine analysis, so providers must move toward interpretation, validation and consulting, where expertise is harder to copy. Retention is also difficult.

Trends •Cloud-Native Platforms and Federated Analysis: Providers are shifting from local servers to cloud platforms where analysis comes to the data rather than the reverse. Federated approaches let hospitals and biobanks keep data in their own jurisdiction while sharing models and results, and trusted research environments are becoming standard for population studies. Workflow standards such as Nextflow, the Common Workflow Language and the Global Alliance for Genomics and Health interfaces improve portability and reproducibility, and clients increasingly expect subscription access to managed pipelines with audit records.

•Single-Cell, Spatial, Long-Read and AI-Enabled Analysis: New measurement methods need new analytical services. Single-cell and spatial studies produce maps of gene activity in tissue, long-read sequencing resolves structural variants and complete genomes, including the Human Pangenome Reference published in 2023, and proteomics and metabolomics add other layers. Providers are adding machine learning models for cell annotation, variant effect prediction and target ranking, and are offering validated, explainable outputs that suit regulatory use in clinical development.

Sequence analysis and data processing lead because every sequencing study needs alignment, variant calling and annotation, while cloud platforms and consulting grow as clients seek secure, scalable and interpretable results. Sequence analysis and data processing is the largest service category because every genomic, transcriptomic or epigenomic study needs quality control, alignment, variant calling, annotation and reporting, and many laboratories lack the staff to do this at scale. Standard pipelines are partly automated, so providers compete on speed, accuracy and documented validation. Data management, storage and cloud platforms cover secure storage, access control, metadata handling and managed compute, and demand is rising as datasets reach population scale and customers want audit trails. Custom software and pipeline development serves clients with unusual assays or integration needs, including connections to laboratory information systems and electronic health records. Consulting and study design advise on sample size, statistical methods, biomarker strategy and regulatory submissions, and carry higher margins because they rely on scarce expertise. Training and support build in-house skills and keep tools operating. Through 2031, cloud and managed platforms and consulting are expected to grow faster than routine processing, which is becoming more automated, and providers are likely to bundle several services into long-term partnerships rather than selling single projects. Long contracts and recurring subscriptions are expected to give providers more predictable revenue than one-off projects by the end of the forecast period.


Genomics leads because sequencing is the most mature and widely used data source, while proteomics, single-cell transcriptomics and integrated multi-omics expand as instruments improve and researchers seek deeper biological context. Genomics is the largest area because whole-genome, exome and targeted sequencing are widely used in research, clinical diagnosis, agriculture and public health, and the analytical methods are well developed. Services include variant calling, structural variant detection, genome assembly, population analysis and interpretation against reference databases. Transcriptomics, including bulk and single-cell RNA analysis, is growing quickly as laboratories study cell types and disease states, and it needs specialised methods for normalisation, clustering and trajectory analysis. Proteomics, using mass spectrometry and affinity platforms, produces complex data that needs peptide identification, quantification and statistical handling, and it is gaining attention for biomarker discovery as large cohort studies are completed. Metabolomics and lipidomics support nutrition, toxicology and disease research, and depend on curated spectral libraries. Epigenomics and multi-omics integration combine methylation, accessibility and other layers with expression and genetic data, and are the most technically demanding. Through 2031, integrated multi-omics and single-cell services are expected to grow fastest, while genomics remains the base of revenue and clinical interpretation continues to expand. Providers that can combine several data types in one validated workflow, with clear documentation of methods and quality checks, are likely to win the largest and longest contracts. Standard reference datasets and shared benchmarks should also make results easier to compare across studies and laboratories.


Drug discovery and development lead because pharmaceutical and biotechnology companies outsource early target identification, biomarker analysis and trial data work, while clinical diagnostics and surveillance grow with sequencing in healthcare. Drug discovery and development is the largest application because computational analysis supports target identification, compound screening, biomarker selection, patient stratification and analysis of clinical trial omics data. Companies use outsourced experts to speed early programmes and to handle peaks in workload without hiring permanent teams. Clinical diagnostics and precision medicine need validated pipelines for tumour profiling, inherited disease testing, pharmacogenomics and newborn screening, with strong requirements for accuracy, traceability and reporting standards, and this segment is expected to grow steadily as sequencing enters routine care. Agricultural and animal genomics support breeding, trait discovery, disease resistance and genomic selection, particularly where large breeding programmes exist. Microbiome and infectious disease surveillance use metagenomic and pathogen sequencing to track outbreaks, antimicrobial resistance and microbial communities in people, food and the environment, and public health agencies increased investment after the pandemic. Academic and basic research remains a broad customer base that depends on grant funding and often uses core facilities and open tools. Through 2031, clinical and surveillance uses should gain share, while pharmaceutical demand remains the largest source of revenue and the main driver of premium services. Regulatory acceptance of computational evidence will also influence adoption.


Pharmaceutical and biotechnology companies lead because they have the largest budgets and the greatest need for specialised analysis, while hospitals, agricultural firms and public agencies increase use as data-driven decisions spread. Pharmaceutical and biotechnology companies are the largest users because they run many programmes at once, generate large omics datasets in discovery and clinical studies, and value speed, regulatory-grade documentation and access to specialists. Large firms often keep core teams and use outside providers for peaks and specialised methods, while small biotechnology companies depend on providers for most analysis. Academic and research institutes are a large but price-sensitive group that use institutional core facilities, collaborations and open-source tools, and buy services for large projects that exceed local capacity. Hospitals and clinical laboratories need reliable interpretation of patient sequencing and are adopting validated pipelines, cloud reporting and decision support, and their demand rises as genomic testing is reimbursed in more health systems. Agricultural and food companies use analysis for breeding, traceability, food safety and microbial testing. Government and public health agencies fund pathogen surveillance, national genome programmes and biobanks, and prefer secure, sovereign environments. Through 2031, hospitals and public agencies are expected to be the fastest growing users, while pharmaceutical customers remain the leading source of revenue and favour long-term strategic partnerships with a small number of providers. Procurement is gradually moving toward framework agreements with preferred providers.


North America leads because the United States combines the largest pharmaceutical and biotechnology industry, major genomic research funding, advanced cloud infrastructure and a deep supply of data scientists. The National Institutes of Health, the Department of Veterans Affairs Million Veteran Program, the All of Us Research Program and large academic medical centres generate and analyse extensive genomic data, and companies such as Illumina, Thermo Fisher, DNAnexus and many specialist providers are based in the region. Clinical use is expanding as insurers cover more sequencing for cancer and rare disease, although a federal court vacated the Food and Drug Administration's rule on laboratory developed tests in March 2025, leaving oversight of in-house assays to existing laboratory regulation. Data security expectations for controlled-access research data tightened in 2025, increasing demand for compliant environments. Canada contributes through national genomics funding and a strong health data research network, and Mexico is an emerging participant. Through 2031, growth is expected from precision oncology, artificial intelligence enabled drug discovery and managed cloud platforms, with competition from in-house teams and open tools limiting prices. Workforce competition and rising cloud costs are the main constraints on margins, so providers focus on specialised interpretation and long-term partnerships.

Europe has strong scientific infrastructure, a large biopharmaceutical sector and some of the most developed rules on data protection, which shapes how services are offered. The European Bioinformatics Institute, ELIXIR, national genomics programmes and the 1+ Million Genomes initiative support shared standards and large cohorts. The United Kingdom has Genomics England, UK Biobank and the National Health Service genomic medicine service, which create demand for secure analysis environments. Germany, France, Switzerland, the Netherlands, Denmark and the Nordic countries have large research and pharmaceutical customers. The European Health Data Space regulation, in force since March 2025, will gradually set rules for secondary use of health data, favouring trusted research environments and interoperable formats, while the General Data Protection Regulation continues to require careful handling of genetic data. The In Vitro Diagnostic Regulation raises validation expectations for clinical software. Providers must adapt to national differences in reimbursement and data localisation. By 2031, growth should come from federated analysis, clinical genomics and cross-border research networks, supported by public funding and cooperation between hospitals and academic centres. Funding programmes that link national health systems with research institutes are expected to keep demand for compliant analysis steady through 2031.

Asia-Pacific is the fastest growing region because of expanding sequencing capacity, government genomic programmes and a growing pharmaceutical and contract research industry. China has large sequencing companies such as BGI and Novogene that offer integrated sequencing and analysis at competitive prices, and regulations on human genetic resources and data localisation influence cross-border work. Japan has national biobank projects and a strong research base, South Korea has a national bio big data programme, and Singapore's population genomics initiative supports regional research and clinical use. Australia has the Genomics Australia programme and active genomic medicine networks. India has a large and increasingly skilled informatics workforce and a growing cost-competitive service sector, supported by national genome initiatives and domestic rare disease programmes. Southeast Asian countries are investing in public health sequencing and agricultural genomics. Barriers include differing regulations, fragmented data standards and varying availability of cloud services. By 2031, the region is expected to supply a larger part of global analysis capacity, serve its own healthcare and agricultural needs and increase exports of analysis services. Rising investment in cloud and high-performance computing is expected to improve local capacity and reduce reliance on overseas analysis.

Latin America is a smaller but developing region where demand is driven by public health, agricultural genomics and academic research. Brazil is the largest market, with university groups, national genome projects, public laboratories such as Fiocruz and a strong agricultural research base that uses genomics for crops and livestock. Mexico, Argentina, Chile, Colombia and Peru have research programmes in population genetics, rare disease and infectious disease surveillance, and many expanded pathogen sequencing capacity during the pandemic. Chile and Brazil have also built regional genomic collaborations that include underrepresented ancestry groups, which is important for better variant interpretation. Hospitals and private laboratories are beginning to adopt clinical sequencing, especially in oncology, but reimbursement is limited. Barriers include funding volatility, import costs for instruments, limited cloud and high-performance computing infrastructure, a shortage of trained staff and data protection laws that vary by country. Providers often partner with local institutions and use remote cloud analysis. By 2031, growth is expected to come from agriculture, public health surveillance and selective clinical adoption in larger private health systems. Regional training programmes and partnerships with international institutes should gradually improve local analytical capability and data sharing.

The Middle East and Africa are early-stage but growing, with national investments in the Gulf and rising research capacity in parts of Africa. Saudi Arabia, the United Arab Emirates and Qatar have large national genome programmes, including the Emirati Genome Programme and the Qatar Genome Programme, which create demand for data storage, analysis and interpretation, particularly for inherited disorders common in the region. Governments are investing in sovereign cloud and data centres to keep genetic data within national borders. Israel has a strong technology and life sciences sector that produces start-ups in computational biology. In Africa, the H3Africa initiative, the Africa Centres for Disease Control and Prevention and institutes in South Africa, Nigeria, Kenya, Uganda and Rwanda support genomic research and pathogen surveillance, and the region contains the greatest human genetic diversity, which makes reference data valuable. Barriers include funding, limited computing infrastructure, a shortage of trained staff, power and connectivity limits and fragmented regulation. By 2031, growth is expected from Gulf national programmes, public health surveillance networks and training partnerships with global institutions. Sustained funding and shared infrastructure will determine how quickly these programmes translate into routine clinical and surveillance services.

2025: Illumina agrees to acquire SomaLogic: The planned acquisition of the proteomics company adds protein measurement to Illumina's sequencing offering and increases demand for integrated multi-omics analysis.

March 2025: European Health Data Space regulation enters into force: The regulation sets common rules for primary and secondary use of health data in the European Union, with obligations phasing in over several years.

March 2025: US court vacates FDA rule on laboratory developed tests: A federal court in Texas set aside the agency's final rule, leaving laboratories to continue operating under existing clinical laboratory regulation.

2025: NIH tightens security expectations for controlled-access data: New requirements affecting researchers who use controlled-access human data increased demand for secure, compliant analysis environments.

October 2024: Nobel Prize in Chemistry recognises protein design and structure prediction: David Baker, Demis Hassabis and John Jumper were honoured, highlighting the role of computational methods in biology.

May 2023: Human Pangenome Reference published: The first draft pangenome, based on 47 individuals, improved reference data for variant detection across diverse ancestries.


Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Bioinformatics Services Market with its segments and regional outlook
• Various drivers and challenges
• Ongoing trends and developments
• Key developments and regulatory milestones

By Service Type
• Sequence analysis and data processing
• Data management, storage and cloud platforms
• Custom software and pipeline development
• Consulting and study design
• Training and support

By Omics Type
• Genomics
• Transcriptomics
• Proteomics
• Metabolomics and lipidomics
• Epigenomics and multi-omics integration

By Application
• Drug discovery and development
• Clinical diagnostics and precision medicine
• Agricultural and animal genomics
• Microbiome and infectious disease surveillance
• Academic and basic research

By End User
• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Hospitals and clinical laboratories
• Agricultural and food companies
• Government and public health agencies